PMID- 38260153
OWN - NLM
STAT- MEDLINE
DCOM- 20240124
LR  - 20240306
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 14
DP  - 2023
TI  - Combined obesity- and lipid-related indices are associated with hypogonadism in 
      Chinese male patients with type 2 diabetes: a cross-sectional study.
PG  - 1319582
LID - 10.3389/fendo.2023.1319582 [doi]
LID - 1319582
AB  - BACKGROUND: There is insufficient attention to hypogonadism in Chinese males with 
      type 2 diabetes mellitus (T2DM). We evaluated the relationship between Combined 
      obesity- and lipid-related indices [Visceral Adiposity Index (VAI), Chinese 
      Visceral Adiposity Index (CVAI), Triglyceride Glucose Index (TyG) and Lipid 
      Accumulation Product (LAP)] with total testosterone (TT) and analyzed the 
      predictive capability of the respective cut-off values. METHODS: We recruited 958 
      hospitalized male patients with T2DM at the Affiliated Hospital of Qingdao 
      University, collected baseline data and four calculated indices, and obtained 
      their dominance ratio (OR) and corresponding 95% confidence intervals (CI) with 
      TT by multivariate logistic regression. Receiver operating characteristic (ROC) 
      curves were then used to determine cutoff values in predicting hypogonadism (TT< 
      12 nmol/L), and we also analyzed the combinations between the different indices. 
      RESULTS: VAI, CVAI, TyG, and LAP all have satisfactory predictive capabilities. 
      The test capability (sensitivity and specificity) of all four indices was better 
      or not worse than that of body mass index (BMI), homeostasis model assessment of 
      insulin resistance (HOMA-IR) and waist circumference (WC). All four indices were 
      effective predictors of hypogonadism at their respective cutoff values 
      (VAI >/= 2.284, CVAI >/= 145.779, TyG >/= 4.308, and LAP >/= 59.850). Of these, LAP had 
      the largest area under the curve (AUC, AUC = 0.852, Std. Error = 0.014, 95% CI = 
      0.818-0.873). However, the predictive capability of the combined indices was not 
      significantly improved over the individual indices. CONCLUSIONS: VAI, CVAI, TyG, 
      and LAP are sensitive indices for predicting hypogonadism in Chinese male 
      patients with T2DM. Considering the need for concise and accurate indices in 
      clinical practice, we suggest LAP as a commonly used index.
CI  - Copyright (c) 2024 Yu, Wang, Xu, Li and Wang.
FAU - Yu, Yongzhuo
AU  - Yu Y
AD  - Department of Endocrinology, the Affiliated Hospital of Qingdao University, 
      Qingdao, China.
FAU - Wang, Yunyang
AU  - Wang Y
AD  - Department of Endocrinology, the Affiliated Hospital of Qingdao University, 
      Qingdao, China.
FAU - Xu, Lili
AU  - Xu L
AD  - Department of Endocrinology, the Affiliated Hospital of Qingdao University, 
      Qingdao, China.
FAU - Li, Wenxuan
AU  - Li W
AD  - Department of Endocrinology, the Affiliated Hospital of Qingdao University, 
      Qingdao, China.
FAU - Wang, Yangang
AU  - Wang Y
AD  - Department of Endocrinology, the Affiliated Hospital of Qingdao University, 
      Qingdao, China.
LA  - eng
PT  - Journal Article
DEP - 20240108
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 3XMK78S47O (Testosterone)
RN  - IY9XDZ35W2 (Glucose)
RN  - 0 (Triglycerides)
SB  - IM
MH  - Humans
MH  - Male
MH  - Cross-Sectional Studies
MH  - *Diabetes Mellitus, Type 2/complications
MH  - Obesity/complications
MH  - Testosterone
MH  - Glucose
MH  - Triglycerides
MH  - *Hypogonadism/complications
MH  - China/epidemiology
PMC - PMC10801025
OTO - NOTNLM
OT  - Chinese visceral adiposity index
OT  - hypogonadism
OT  - lipid accumulation product
OT  - triglyceride glucose index
OT  - type 2 diabetes mellitus
OT  - visceral adiposity index
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2024/01/23 12:44
MHDA- 2024/01/24 06:44
PMCR- 2023/01/01
CRDT- 2024/01/23 10:34
PHST- 2023/10/11 00:00 [received]
PHST- 2023/12/15 00:00 [accepted]
PHST- 2024/01/24 06:44 [medline]
PHST- 2024/01/23 12:44 [pubmed]
PHST- 2024/01/23 10:34 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2023.1319582 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2024 Jan 8;14:1319582. doi: 
      10.3389/fendo.2023.1319582. eCollection 2023.